We are live on ! Find out more
KALA icon

KALA BIO

40 hedge funds and large institutions have $30.9M invested in KALA BIO in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.74% less ownership

Funds ownership: 46.74% → 39% (-7.7%)

13% less funds holding

Funds holding: 46 → 40 (-6)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

53% less call options, than puts

Call options by funds: $69K | Put options by funds: $146K

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

70% less capital inflows, than outflows

Capital inflows: $5.43M | Capital outflows: $18.2M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
40
Holders Change
-6
Holders Change %
-13.04%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
3
Reduced
9
Closed
15
Calls
$69​K
Puts
$146​K
Net Calls
-⁠$77​K
Net Calls Change
+$442​K

KALA Hedge Fund Activity: Q4 2021 in Review

40 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2021, worth a combined $30.9M — down 61% from $79.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of KALA and 9 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 3 added.

The largest buyer was Bank of America, adding an estimated $835K. The largest seller was OrbiMed, exiting entirely with an estimated $9.01M sold.

  • 40 institutional investors held KALA BIO (KALA) as of Q4 2021, down from 46 in Q3 2021.
  • Funds reported $30.9M of KALA BIO stock for Q4 2021, down 61% quarter-over-quarter.
  • 9 funds opened new KALA BIO positions in Q4 2021 and 15 closed out, a net change of -6 holders.
  • The largest KALA BIO buyer in Q4 2021 was Bank of America, an estimated $835K added.
  • The largest KALA BIO seller in Q4 2021 was OrbiMed, an estimated $9.01M sold.

Based on aggregated 13F filings for Q4 2021.